Programmed death-ligand 1 (PD-L1) expression in Hodgkin’s lymphoma among Peruvian patients

Authors

  • María del Rosario Villa Robles Instituto Nacional de Enfermedades Neoplásicas (INEN). Lima, Perú. Laboratorio de Inmunohistoquímica del INEN. Lima, Perú. Bióloga(o). Coordinadora del laboratorio de inmunohistoquímica del INEN. https://orcid.org/0000-0001-8780-3700
  • Sandro Casavilca Zambrano Instituto Nacional de Enfermedades Neoplásicas (INEN). Lima, Perú. Equipo funcional de patología quirúrgica del INEN. Lima, Perú. Médico cirujano, especialista en anatomía patológica. Doctor en neurociencias. Director del Departamento de Patología del INEN. https://orcid.org/0000-0001-8406-739X
  • Ruddy Liendo Picoaga Instituto Nacional de Enfermedades Neoplásicas (INEN). Lima, Perú. Banco de tejidos tumorales del INEN. Lima, Perú. Bióloga(o). Magister en biología molecular. https://orcid.org/0000-0003-3570-8802
  • Ana Cecilia Barrionuevo Ponte Universidad Peruana de Ciencias Aplicadas (UPC). Lima, Perú. Interna de medicina. https://orcid.org/0000-0001-7425-0377
  • Ana Sofía Barrionuevo Ponte Universidad Peruana de Ciencias Aplicadas (UPC). Lima, Perú. Interna de medicina. https://orcid.org/0000-0002-9227-0125
  • Carlos Barrionuevo Cornejo Instituto Nacional de Enfermedades Neoplásicas (INEN). Lima, Perú. Equipo funcional de patología quirúrgica del INEN. Lima, Perú. Universidad Nacional Mayor de San Marcos (UNMSM). Lima, Perú. Médico cirujano, especialista en anatomía patológica. Doctor en medicina. Jefe del equipo funcional de patología quirúrgica del INEN. https://orcid.org/0000-0003-2474-914X

DOI:

https://doi.org/10.24265/horizmed.2022.v22n3.02

Keywords:

Hodgkin Disease, Proteins , Neoplasms, Immunohistochemistry

Abstract

Objective: Various studies on Hodgkin’s lymphoma (HL) have determined programmed death-ligand 1 (PD-L1) expression in Hodgkin and Reed-Sternberg (HRS) cells, with variable results. This protein has gained relevance for its role in the
immune response in malignant neoplasms. This work aimed to determine PD-L1 immunohistochemical expression in HRS cells and its relationship with age, sex, clinical stage and overall survival (OS) in a cohort of Peruvian patients. Materials and methods: Twenty-five (25) biopsies from patients diagnosed with HL were assessed, which allowed determining PD-L1 immunohistochemical expression in HRS cells in relation to OS and clinical data of the patients. Results: All cases showed PD-L1 expression in more than 1 % of tumor cells. There was no statistically significant difference in OS when two groups were compared in terms of PD-L1 expression with a cut-off point of 50 %, clinical stage (CS), age and sex. Conclusions: High PD-L1 expression was found in pre-treatment HL tumors. No association was found between PD-L1 expression, OS, age, sex or CS. Further studies with a larger number of patients are necessary to reassess the prognostic
impact of the expression of this protein in HL.

Downloads

Download data is not yet available.

References

Stein H, Pileri S, Weiss L. Hodgkin lymphomas: Introduction. In:

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H,

eds. WHO classification of tumors of haematopoietic and lymphoid

tissues. 4th ed. Lyon: International Agency for Research on Cancer;

p. 424-30.

De Re V, Caggiari L, Repetto O, Mussolin L, Mascarin M. Classical

Hodgkin’s lymphoma in the era of immune checkpoint inhibition. J

Clin Med. 2019; 8(10): 1596.

Xie W, Medeiros LJ, Li S, Yin CC, Khoury JD, Xu J. PD-1/PD-L1

pathway and its blockade in patients with classic hodgkin lymphoma

and non-Hodgkin large-cell lymphomas. Curr Hematol Malig Rep.

; 15(4): 372-81.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A.

Global cancer statistics 2018: GLOBOCAN estimates of incidence and

mortality worldwide for 36 cancers in 185 countries. Cancer J Clin.

; 68(6): 394-424.

Kumar V, Abbas AK, Aster J. Evasion of immune surveillance. In:

Pathologic basis of disease. 2021. p. 309-13.

Paydas S, Bağır E, Seydaoglu G, Ercolak V, Ergin M. Programmed

death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded

RNA (EBER) expression in Hodgkin lymphoma. Ann Hematol. 2015;

(9): 1545-52.

Hollander P, Kamper P, Smedby KE, Enblad G, Ludvigsen M,

Mortensen J, et al. High proportions of PD-1(+) and PD-L1(+)

leukocytes in classical Hodgkin lymphoma microenvironment are

associated with inferior outcome. Blood Adv. 2017; 1(18): 1427-39.

Hollander P, Amini RM, Ginman B, Molin D, Enblad G, Glimelius I.

Expression of PD-1 and PD-L1 increase in consecutive biopsies in

patients with classical Hodgkin lymphoma. PLoS One. 2018; 13(9):

e0204870.

Tiemann M, Samoilova V, Atiakshin D, Buchwalow I.

Immunophenotyping of the PD-L1-positive cells in

angioimmunoblastic T cell lymphoma and Hodgkin disease. BMC

Res Notes. 2020; 13(1): 139.

Volaric A, Bacchi CE, Gru AA. PD-1 and PD-L1 immunohistochemistry

as a diagnostic tool for classic Hodgkin lymphoma in small-volume

biopsies. Am J Surg Pathol. 2020; 44(10): 1353-66.

Romero JM, Totten SPS. Anti-PD-1 shows promise against advanced

paediatric Hodgkin lymphoma. The Lancet. 2020; 21: e126.

Jalali S, Price-Troska T, Bothun C, Villasboas J, Kim H-J, Yang Z-Z, et al.

Reverse signaling via PD-L1 supports malignant cell growth and

survival in classical Hodgkin lymphoma. Blood Cancer J. 2019;

(3): 22.

Simon R, Mirlacher M, Sauter G. Tissue microarrays. Biotechniques.

; 36(1): 98-105.

Zafra SG, Flórez VO, Gónzales RC. Influencia del método de

desparafinación y el tiempo de almacenamiento en la extracción de

DNA a partir de tejidos de archivo. Rev Univ Ind Santander, Salud.

; 36(2): 73-9.

Pardo MJ, Panizo A, Martínez L. Valoración del sistema de polímeros

de dextrano EnVision (PDE) en la detección inmunohistoquímica. Rev

Española Patol. 1998; 31(1): 9-16.

Roemer MGM, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H,

et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin

lymphoma and predict outcome. J Clin Oncol. 2016; 34(23): 2690-7.

Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M,

et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s

lymphoma. N Engl J Med. 2015; 372(4): 311-9.

Armand P, Shipp MA, Ribrag V, Michot J-M, Zinzani PL, Kuruvilla J, et al.

Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J

Clin Oncol. 2016; 34(31): 3733-9.

Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S,

et al. Nivolumab for classical Hodgkin’s lymphoma after failure of

both autologous stem-cell transplantation and brentuximab vedotin:

A multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol.

; 17(9): 1283-94.

Steidl C, Telenius A, Shah SP, Farinha P, Barclay L, Boyle M, et al.

Genome-wide copy number analysis of Hodgkin Reed-Sternberg

cells identifies recurrent imbalances with correlations to treatment

outcome. Blood. 2010; 116(3): 418-27.

Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in

tolerance and immunity. Annu Rev Immunol. 2008; 26: 677- 04.

Birkenmeier K, Dröse S, Wittig I, Winkelmann R, Käfer V, Döring C, et al.

Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma are

highly dependent on oxidative phosphorylation. Int J Cancer. 2016;

(9): 2231-46.

Greaves P, Clear AJ, Owen A, Wilson A, Matthews J, Calaminici M,

et al. The PD1/PD-L1 Axis in the Classical Hodgkin Lymphoma

Microenvironment: PD-1 Is rarely expressed but identifies patients

with high-risk disease. Blood. 2011; 118(21): 1560.

Good-Jacobson KL, Szumilas CG, Chen L, Sharpe AH, Tomayko MM,

Shlomchik MJ. PD-1 regulates germinal center B cell survival and

the formation and affinity of long-lived plasma cells. Nat Immunol.

; 11(6): 535-42.

Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M,

Tashima M, et al. PD-1-PD-1 ligand interaction contributes to

immunosuppressive microenvironment of Hodgkin lymphoma.

Blood. 2008; 111(6): 3220-4.

Greaves P, Clear A, Owen A, Iqbal S, Lee A, Matthews J, et al. Defining

characteristics of classical Hodgkin lymphoma microenvironment

T-helper cells. Blood. 2013; 122(16): 2856-63.

Muenst S, Hoeller S, Dirnhofer S, Tzankov A. Increased programmed

death-1+ tumor-infiltrating lymphocytes in classical Hodgkin

lymphoma substantiate reduced overall survival. Hum Pathol. 2009;

(12): 1715-22.

Downloads

Published

2022-09-27

How to Cite

1.
Villa Robles M del R, Casavilca Zambrano S, Liendo Picoaga R, Barrionuevo Ponte AC, Barrionuevo Ponte AS, Barrionuevo Cornejo C. Programmed death-ligand 1 (PD-L1) expression in Hodgkin’s lymphoma among Peruvian patients. Horiz Med [Internet]. 2022Sep.27 [cited 2025May2];22(3):e1927. Available from: https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/1927

Issue

Vol. 22 No. 3 (2022): July - September

Section

Original article

License

Copyright (c) 2022 Horizonte Médico (Lima)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).